Target receptors in diabetic neuropathy: Key insights & implications

Diabetic neuropathy (DN) is a debilitating complication of diabetes mellitus (DM), characterized by nerve damage resulting from chronic hyperglycemia. This condition affects a significant proportion of diabetic patients, leading to symptoms such as weakness, numbness, and pain, particularly in the extremities. The pathogenesis of DN is complex and involves metabolic, vascular, and neurotrophic factors. At the core of its development are various receptors that mediate and modulate the underlying biochemical and cellular processes. Key receptors implicated in DN include the advanced glycation end-product receptor (RAGE), which is involved in oxidative stress and inflammation. Additionally, transient receptor potential channels, namely TRP channels, particularly TRPV1 and TRPA1, play an important role in the sensation of pain and thermal stimuli, contributing to the sensory abnormalities observed in DN. Insulin and insulin-like growth factor receptors also play significant roles, as insulin signaling is crucial for neuronal survival and function. Furthermore, purinergic receptors, specifically the P2X and P2Y subtypes, are involved in neuroinflammation and pain transmission. Understanding the roles and interactions of these receptors provides valuable insights into the pathophysiology of DN and highlights potential therapeutic targets. Future research focusing on modulating these receptor pathways holds promise for developing effective treatments to alleviate symptoms and potentially reverse the progression of DN.